On March 7th 2013, following an invitation from Paul Anderson, Dale Boger & Bill Greenlee (Section Heads for the Drug Discovery & Design Section), Michael was appointed as a Faculty Member of the Drug Discovery & Design Section (Pharmacology & Drug Discovery Faculty).
Vice President Discovery Research for Karolinska Development and CEO of KDev Exploratory AB, a subsidiary of Karolinska Development
Managing Director, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark
Chief Scientist, the Structural Genomics Consortium, University of Oxford, UK
Director, Structural Chemistry, Pharmacia Oncology Research, Milano
1992-1993 Postdoc with Prof R Ladenstein in the Department of Structural Biochemistry, The Karolinska Institute, Stockholm, Sweden
1988-1992 PhD Department of Molecular Biology and the Ludwig Institute for Cancer Research, Uppsala, Sweden.
1983-1988 MSc from the Swedish University of Agricultural Sciences, Uppsala in Agronomy with Biotechnology direction
• Protein based science, with emphasis on molecular biophysics as well as structural and chemical biology.
• Phosphorylation dependent signaling, the ubiquitin system, epigenetics and protein-protein interactions.
• Drug discovery and development, particularly focused on enzyme inhibition
• Identification and evaluation of research projects from academia and industry, for further development and funding by Karolinska Development
In the role of Faculty Member, Michael Sundström contributes recommendations and reviews to the Drug Discovery & Design Section in the Pharmacology & Drug Discovery Faculty, writing brief accessible comments to summarize the value of the articles and adding rating score.
The Faculty comprises Heads of Faculty, Heads of Section, Faculty Members and Associate Faculty Members, as well as an International Advisory Board.
Read more about F1000Prime »